GlassScriptPhysician profile
Zhenia Tornes
NPI 1952790693
$1,995.52
in general payments reported to CMS, 2019-2025
13 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $398 · 2023: $703 · 2024: $182 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.23 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $534.89 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $448.12 | 2021-2025 | |
| Abbvie INC. | $439.92 | 2021-2023 | |
| Pfizer INC. | $124.66 | 2021-2024 | |
| Myriad Women'S Health, INC. | $110.54 | 2023 | Myrisk |
| Avion Pharmaceuticals | $86.28 | 2021-2023 | Balcoltra |
| Agile Therapeutics, INC. | $65.21 | 2021-2022 | |
| Exeltis, USA INC. | $48.55 | 2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $47.07 | 2025 | |
| Shield Therapeutics INC | $27.63 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $24.83 | 2025 | Aptima, Thinprep 2000 Processor |
| Millicent US INC | $19.64 | 2021 | |
| Therapeuticsmd, INC. | $18.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhenia Tornes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.